A carregar...
Rilpivirine and Doravirine have complementary efficacies against NNRTI-Resistant HIV-1 mutants
BACKGROUND: Rilpivirine (RPV) is the latest non-nucleoside reverse transcriptase inhibitor (NNRTI) to be FDA-approved to combat HIV-1 infections. NNRTIs inhibit the chemical step in viral DNA synthesis by binding to an allosteric site located about 10 Å from the polymerase active site of reverse tra...
Na minha lista:
| Publicado no: | J Acquir Immune Defic Syndr |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4942337/ https://ncbi.nlm.nih.gov/pubmed/27124362 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0000000000001031 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|